A Long-term Observational Study in Participants Who Have Received PBGENE-HBV

NCT07254208 · tracked via the Priya Life Science USA tracker

Sponsor

Precision BioSciences, Inc.

Phase

Observational

Started

2025-12-25

Last updated

2026-04-22

Condition(s) studied

Chronic HBV Infection

Investigational drug(s) / intervention(s)

PBGENE-HBV

PBGENE-HBV: PBGENE-HBV is the investigational product administered in the parent study. This LTFU study is non-interventional; no investigational product given.

Study summary

Participants who received at least one dose of PBGENE-HBV will be enrolled in this LTFU study.

Eligibility

Sex

ALL

Min age

19 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: 1. Participant has received at least 1 dose of PBGENE-HBV investigational product in a prior clinical study 2. Participant, or their legally authorized representative, has provided signed informed consent. Exclusion Criteria: * N/A

Primary outcome measure(s)

Safety to assess frequency, severity, and outcome of delayed adverse events — 15 years
Delayed adverse events

Trial sites (4)

Facility	City	Region
Massachusetts General Hospital/Harvard University	Boston	Massachusetts
Queen Mary Hospital, University of Hong Kong	Hong Kong	Hong Kong
ICS ARENSIA Exploratory Medicine SRL	Chisinau	Moldova
New Zealand Clinical Research	Auckland	New Zealand

More Precision BioSciences, Inc. trials in the USA

PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD) Recruiting

Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07254208 on ClinicalTrials.gov ↗ ← All trials in the USA